Choksi Laborator

What is the technical trend for Choksi Laborator?

As of June 3, 2025, Choksi Laborator's technical trend has shifted to bullish, supported by strong daily moving averages and monthly indicators, despite some mildly bearish signals on the weekly MACD and KST.

As of 3 June 2025, the technical trend for Choksi Laborator has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands confirm a bullish trend. Despite the weekly MACD and KST showing mildly bearish signals, the monthly MACD and KST are bullish, reinforcing the overall positive outlook. Dow Theory also indicates a bullish trend on both weekly and monthly time frames. The stock has shown significant returns compared to the Sensex, further highlighting its strength in the market.

how big is Choksi Laborator?

As of March 2024, Choksi Laboratories Ltd has a market capitalization of 100.00 Cr, with net sales of 41.50 Cr and a net profit of 1.29 Cr over the last four quarters. Shareholder's funds are valued at 22.21 Cr, and total assets amount to 61.56 Cr.

Market Cap: Choksi Laboratories Ltd has a market capitalization of 100.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 41.50 Cr, and the sum of Net Profit for the same period is 1.29 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. Shareholder's Funds are valued at 22.21 Cr, and Total Assets amount to 61.56 Cr.

Who are in the management team of Choksi Laborator?

As of March 2023, the management team of Choksi Laborator includes Sunil Choksi (Managing Director & CEO), Stela Choksi, Vyangesh Choksi (CFO), Himika Choksi, and several independent directors, overseeing the company's operations and governance.

As of March 2023, the management team of Choksi Laborator consists of the following individuals:<BR><BR>1. Sunil Choksi - Managing Director & CEO<BR>2. Stela Choksi - Whole-time Director<BR>3. Vyangesh Choksi - Whole Time Director & CFO<BR>4. Sudarshan Shastri - Independent Director<BR>5. N K Mani - Independent Director<BR>6. Himika Choksi - Whole-time Director<BR>7. Raghmendra Singh - Independent Director<BR>8. Prakhar Dubey - Company Secretary & Compliance Officer<BR>9. Meenaxi Patidar - Independent Director<BR><BR>This team includes a mix of executive and independent directors, overseeing various aspects of the company's operations and governance.

What does Choksi Laborator do?

Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare sector and has a market cap of Rs 105 Cr. As of December 2024, it reported net sales of 10 Cr and a net profit of 0 Cr.

Overview:<BR>Choksi Laboratories Ltd provides contract testing and analytical services in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated on 29 January 1993, Choksi Laboratories Ltd has been operational since its inception. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot:<BR>Net Sales: 10 Cr (Quarterly Results - Dec 2024) <BR>Net Profit: 0 Cr (Quarterly Results - Dec 2024) <BR>Market Cap: Rs 105 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 74.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.26 <BR>Return on Equity: 5.60% <BR>Price to Book: 4.14 <BR><BR>Contact Details:<BR>Address: Survey no 9/1 Gram Kumerdi, Near to Tulshiyana Indl Park Indore Madhya Pradesh : 452010 <BR>Email: compliance_officer@choksi.com <BR>Website: http://www.choksilab.com

Has Choksi Laborator declared dividend?

No Dividend History Available

Who are the peers of the Choksi Laborator?

Choksi Laborator's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. Choksi Laborator has the highest 1-year return at 115.17%, while most peers show below-average growth and varying management risks.

Peers: The peers of Choksi Laborator are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, N G Industries, Centenial Surgic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average or Average management risk. Growth is Below Average for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, and the rest, while Average growth is noted for Poly Medicure, Indegene, Choksi Laborator, and N G Industries. Excellent capital structure is seen at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Below Average or Average capital structure.<BR><BR>Return Snapshot: Choksi Laborator has the highest 1-year return at 115.17%, while Jeevan Scienti. has the lowest at -19.28%. Compared to its peers, Choksi Laborator's return is significantly higher. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Jeevan Scienti., Aspira Pathlab, and Deccan Healthcar.

Who are the top shareholders of the Choksi Laborator?

The top shareholders of Choksi Laborator include promoter Sunil Choksi with 7.51% and public shareholder Sachin Seth with 3.96%. Individual investors hold 52.67%, while foreign institutional investors own 1.94%, and there are no mutual funds invested in the company.

The top shareholders of Choksi Laborator include Sunil Choksi, who is the promoter with the highest holding at 7.51%. Following him, Sachin Seth is the highest public shareholder with a stake of 3.96%. Additionally, individual investors collectively hold a significant portion of the company at 52.67%. The company also has 1.94% held by foreign institutional investors (FIIs), but there are no mutual funds currently invested in it.

Is Choksi Laborator overvalued or undervalued?

As of October 13, 2025, Choksi Laborator is rated attractive but considered overvalued with high valuation ratios, including a PE of 85.25, despite strong stock performance, especially when compared to peers like Apollo Hospitals and Max Healthcare.

As of 13 October 2025, the valuation grade for Choksi Laborator has moved from very attractive to attractive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 85.25, while the Price to Book Value is 5.42, and the EV to EBIT is 33.62, all indicating a premium valuation compared to its peers.<BR><BR>In comparison, Apollo Hospitals, which is also rated attractive, has a significantly lower PE ratio of 70.2 and an EV to EBITDA of 36.12. Max Healthcare, rated as very expensive, has a PE ratio of 92.33, but its high valuation does not justify the premium over Choksi Laborator. Despite Choksi's impressive stock performance, with a year-to-date return of 144.57% compared to the Sensex's 5.36%, the elevated valuation ratios suggest that the stock may be overvalued in the current market environment.

How has been the historical performance of Choksi Laborator?

Choksi Laborator has experienced growth in net sales and operating income from Mar'21 to Mar'25, but its profitability metrics, including profit before and after tax, have fluctuated significantly. The company needs to focus on cost management and operational efficiency despite improved cash flow from operating activities.

Answer:<BR>The historical performance of Choksi Laborator shows a mixed trend over the years, with notable fluctuations in revenue and profitability.<BR><BR>Breakdown:<BR>Choksi Laborator's net sales have shown a consistent upward trajectory, increasing from 25.69 Cr in Mar'21 to 41.78 Cr in Mar'25. Total operating income followed a similar pattern, rising from 28.49 Cr in Mar'20 to 41.78 Cr in Mar'25. The company's operating profit (PBDIT) has also improved, reaching 11.30 Cr in Mar'25 from 3.17 Cr in Mar'20, although the operating profit margin has slightly decreased from 29.73% in Mar'23 to 26.88% in Mar'25. Profit before tax fluctuated significantly, peaking at 3.72 Cr in Mar'23 before dropping to 2.15 Cr in Mar'25. Profit after tax also saw a decline from 3.21 Cr in Mar'23 to 1.52 Cr in Mar'25. The company's total liabilities increased from 59.49 Cr in Mar'23 to 64.79 Cr in Mar'25, while total assets rose from 59.49 Cr to 64.79 Cr in the same period. Cash flow from operating activities improved to 11.00 Cr in Mar'25, maintaining stability compared to previous years. Overall, while Choksi Laborator has shown growth in sales and operating income, its profitability metrics have experienced volatility, indicating a need for strategic focus on cost management and operational efficiency.

When is the next results date for Choksi Laboratories Ltd?

Choksi Laboratories Ltd will announce its results on 25 May 2026.

Choksi Laboratories Ltd is scheduled to declare its results on 25 May 2026.

Are Choksi Laboratories Ltd latest results good or bad?

Choksi Laboratories Ltd's latest Q4 FY26 results show a significant net profit increase of 232.26% and revenue growth of 12.46%, but concerns remain due to low return on equity (6.50%) and a high debt-to-EBITDA ratio (4.91), indicating underlying financial weaknesses. Overall, while there are positive signs, the results are mixed and warrant caution for investors.

Choksi Laboratories Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company reported a net profit of ₹1.03 crores, which is a significant increase of 232.26% compared to the previous quarter. Additionally, revenue grew by 12.46% year-on-year, reaching ₹12.82 crores, and the operating margin improved to 28.39%, up from 24.49% in the previous quarter.<BR><BR>However, there are notable concerns. The return on equity (ROE) remains low at 6.50%, indicating weak capital efficiency. The company also has a high debt-to-EBITDA ratio of 4.91 times, which raises questions about its financial stability. Furthermore, while the quarterly results show improvement, the annual profit stagnated at ₹1.00 crore, unchanged from the previous year, suggesting challenges in translating revenue growth into meaningful profit expansion.<BR><BR>In summary, while there are positive signs in the recent quarterly performance, underlying structural weaknesses and high leverage indicate that the overall results are not entirely favorable. Investors should weigh these factors carefully.

Should I buy, sell or hold Choksi Laboratories Ltd?

Which are the latest news on Choksi Laborator?

Why is Choksi Laboratories Ltd falling/rising?

As of 03-Jun, the stock price of Choksi Laboratories Ltd is stable at 122.00, but it has declined 7.99% over the past week, contrasting with a 19.84% increase over the past month. Despite recent underperformance, the stock has shown significant long-term growth, with a 172.02% rise over three years and an 867.49% increase over five years.

As of 03-Jun, the stock price of Choksi Laboratories Ltd is currently stable at 122.00, showing no change (0.00%). Over the past week, the stock has experienced a decline of 7.99%, which is significantly worse than the Sensex's decline of 2.01%. However, looking at a longer time frame, the stock has risen by 19.84% over the past month, contrasting with the Sensex's drop of 3.34%. <BR><BR>Year-to-date, the stock is down 5.57%, while the Sensex has decreased by 12.76%. Over the past year, Choksi Laboratories Ltd has seen a slight decline of 2.24%, compared to the Sensex's 7.92% drop. Notably, the stock has performed exceptionally well over the longer term, with a 172.02% increase over three years and an impressive 867.49% rise over five years.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.57%. The moving averages suggest that while the stock is above the 20-day, 50-day, and 100-day moving averages, it is below the 5-day and 200-day moving averages. This mixed performance could contribute to investor sentiment regarding the stock's stability. <BR><BR>Additionally, there has been a rise in investor participation, with delivery volume increasing by 8.25% against the five-day average, indicating a growing interest in the stock. The liquidity of the stock is also sufficient for trading, as it is based on 2% of the five-day average traded value.<BR><BR>In summary, while the stock price is currently stable, the recent decline over the past week and mixed performance relative to moving averages may be contributing factors to its current status.